Friday Lectures
Friday, May 2, 2017 3:45 p.m.
Caspary Auditorium
James P. Allison, Ph.D.
Professor and Vivian L. Smith Distinguished Chair of Immunology,
Executive Director of the Immunotherapy Platform
The University of Texas MD Anderson Cancer Center
Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for a Cure
Recommended Readings:
http://thetartan.org/2017/5/1/scitech/immunotherapy
Hazarika M; Chuk MK; Theoret MR; et al. (2017). U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.CLINICAL CANCER RESEARCH. doi: 10.1158/1078-0432
Medina, Patrick J.; Adams, Val R. (2016). PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. PHARMACOTHERAPY. 36(3): 317-334
Sharma, Padmanee; Allison, James P. (2015). Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. CELL. 161(2): 205-214
Robert, Caroline; Schachter, Jacob; Long, Georgina V.; et al. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. NEW ENGLAND JOURNAL OF MEDICINE 372(26): 2521-2532
Sharma, Padmanee; Allison, James P. (2015). The future of immune checkpoint therapy. SCIENCE. 348(6230): 56-61
Gubin, Matthew M.; Zhang, Xiuli; Schuster, Heiko; et al. (2014). Checkpoint blockage cancer immunotherapy targets tumour-specific mutant antigens. NATURE. 515(7528): 577-+
Lipson, Evan J.; Drake, Charles G. (2011). Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. CLINICAL CANCER RESEARCH. 17(22): 6958-6962
